
Turning vision into impact through strategic value investment

Founded 2008 in Hangzhou, China, the Win-Light Family Fund has invested in more than 50 startups across biotechnology, medical devices, advanced material and new energy. With operations in Hangzhou, San Diego, and Boston, we tap into a diverse network of advisors from top research institutes and industry leaders, providing not only capital but also strategic insights to transform breakthrough ideas into scalable businesses.
We seek to harness the power of disruptive technologies that can shape the foundations of a smarter, healthier, and more resilient future.

CHASM develops and manufactures advanced carbon nanotube (CNT) hybrids that enhance product performance across various industries. Their innovative platforms, AgeNT® and NTeC®, enable applications such as transparent conductive films for electronics, conductive additives for EV batteries, and strength-enhancing agents for low-carbon cement.

Clinical Research IO offers a comprehensive eSource system designed to streamline clinical trial workflows. Their integrated solutions include eSource, eConsent, and eRegulatory tools, facilitating remote monitoring and real-time data access for research sites, hospitals, biotech, and pharmaceutical companies.

ConnectM is a clean energy solutions provider dedicated to accelerating the transition to an all-electric future. The company’s proprietary Energy Intelligence Network integrates electrified assets with advanced AI-driven analytics, enabling residential, commercial, and transportation sectors to efficiently reduce reliance on fossil fuels, lower energy costs, and minimize carbon footprints.

Factorial Energy is driving the future of clean energy with its next-generation solid-state battery technology. Through innovations like FEST® and Solstice™, the company addresses key challenges in electric vehicle batteries—boosting safety, efficiency, and sustainability.

HiFiBiO Therapeutics is a biotech company developing curative immunotherapies using its proprietary DIS® platform, which combines single-cell technology and AI to uncover disease drivers, guide antibody discovery, and identify predictive biomarkers for improved clinical outcomes.

Manus Bio engineers microbial cell factories to produce high-value, sustainable ingredients traditionally sourced from plants or petrochemicals. From food and nutrition to personal care and beyond, Manus Bio enables scalable, eco-friendly alternatives that reduce environmental impact.

Investing in enduring innovations where deep science meets lasting value
Dive into our comprehensive blog
Ready to take the next step towards financial prosperity? Reach out and connect with our expert team.